Add-Aspirin Trial A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours - (Joint with University College London and Cardiff University)

  • Carey, Francis, (Investigator)
  • King, Sharon, (Investigator)
  • Steele, Bob (Investigator)
StatusActive
Effective start/end date1/09/1531/07/25

Funding

  • Cancer Research UK: £8,562.50
  • Cancer Research UK (UCL): £111,260.00